E uiga ile-kanesa / togafitiga / togafitiga-faʻafitauli / faʻamaʻi / anal-kanesa / togafitiga

Togafitiga Togafitiga Togafitiga mo le Kanesa Kanesa

Togafitiga faʻafomaʻi o suʻesuʻega suʻesuʻega e aʻafia ai tagata. O faʻataʻitaʻiga faʻafomaʻi i luga o lenei lisi e mo togafitiga o kanesa kanesa. O faʻataʻitaʻiga uma i luga o le lisi e lagolagoina e le NCI.

O faʻamatalaga taua a le NCI e uiga ile faʻataʻitaʻi ile falemaʻi o loʻo faʻamatalaina ai ituaiga ma vaega o faʻataʻitaʻiga ma faʻafefea ona faʻatinoina. Togafitiga faʻafomaʻi e vaʻai i ni auala fou e puipuia ai, iloa ai, pe togafitia ai faʻamaʻi. Atonu e te manaʻo e mafaufau e uiga i le auai i le faʻataʻitaʻiina o togafitiga. Talanoa i lau fomaʻi mo se fesoasoani i le filifiliga pe o se tasi e talafeagai mo oe.

Faʻataʻitaʻiga 1-23 o le 23

Nivolumab i le maeʻa ai o le tuʻufaʻatasia o togafitiga masani i le togafitia o tagata mamaʻi ma le tulaga lamatia maualuga II-IIIB Anal Cancer

Lenei randomized vaega II falemaʻi suʻesuʻega suʻesuʻega pe o le a le lelei o le nivolumab pe a maeʻa tuʻufaʻatasia metality togafitiga e galue ai i le togafitia o tagata gasegase maualuga tulaga lamatia II-IIIB anal kanesa. Immunotherapy ma monoclonal antibodies, pei o le nivolumab, e ono fesoasoani i le tino o le tino i osofaʻiga o le kanesa, ma ono faʻalavelave ai ile mafai o sela tuma e tutupu ma sosolo.

Nofoaga: 744 nofoaga

Nivolumab ma pe leai Ipilimumab i le togafitia o tagata mamaʻi ma Refractory Metastatic Anal Kanesa Kanesa

Lenei vaega II suʻesuʻega suʻesuʻe pe o le a le lelei o le nivolumab ma le leai o le ipilimumab galue i le togafitia o tagata mamaʻi ma le kanesa kanesa kanesa e leʻi tali atu i togafitiga muamua (refactory) ma salalau atu i isi nofoaga i le tino (metastatic). Immunotherapy ma monoclonal antibodies, pei o le nivolumab ma ipilimumab, e ono fesoasoani i le tino o le tino i osofaʻiga o le kanesa, ma ono faʻalavelave ai ile mafai o sela tuma e tutupu ma sosolo.

Nofoaga: 42 nofoaga

Nivolumab ma Ipilimumab i le togafitia o tagata mamaʻi ma le HIV Associated Toe faʻafouina pe Refractory Classical Hodgkin Lymphoma poʻo Tumors Tumau O Na Metastatic pe Le Mafai Ona Aveʻesea e le Taʻotoga.

Lenei vaega I suʻesuʻega suesueina le itu aafiaga ma sili ona lelei tui o le nivolumab pe a tuuina atu ma ipilimumab i le togafitia o tagata mamaʻi ma le puipuia o le siama o le tagata (HIV) fesootai masani Hodgkin lymphoma na toe foi mai i le maeʻa ai o se vaitaimi o le alualu i luma pe le tali atu i togafitiga, po o tuma mautu ia ua salalau i isi nofoaga o le tino pe le mafai ona aveʻesea e ala i se taʻotoga. Immunotherapy ma monoclonal antibodies, e pei o ipilimumab ma nivolumab, ono fesoasoani i le tino o le tino puipuia osofaia le kanesa, ma ono faʻalavelave i le mafai o tumo sela e tutupu ma salalau. Ipilimumab o se vailaʻau e faʻasaga i se molemole taʻua o le cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 faʻatonutonuina se vaega o lau puipuiga i le tapunia i lalo. Nivolumab o se ituaiga o vailaʻau e faʻapitoa mo tagata faʻapolokalameina oti sela 1 (PD-1), o se polotini e nafa ma le faʻatamaʻia o sela puipuia. O le tuʻuina atu o le ipilimumab ma le nivolumab e mafai ona sili atu le lelei ile togafitia o tagata mamaʻi e maua ile HIV masani Hodgkin lymphoma poʻo le tuma faʻatusatusa i le ipilimumab ma le nivolumab naʻo ia.

Nofoaga: 28 nofoaga

O le suʻesuʻega o le XmAb®20717 i mataupu e iai fulufulu tumaʻi filifilia filifilia

Lenei o le Vaega 1, tele fualaʻau, alu i luga fualaʻau faʻateleina suʻesuʻega e faʻamatalaina le MTD / RD ma tulafono a le XmAb20717, e faʻamatala ai le saogalemu ma le faʻapalepaleina, e iloilo ai PK ma le puipuia o le tino, ma muamua iloiloina anti-tumo gaioiga o XmAb20717 i mataupu ma filifilia alualu i luma tuma.

Nofoaga: 15 nofoaga

Suesuega Immuno-togafitiga Suesuega e suʻesuʻe ai le Saogalēmū ma le aoga o Nivolumab, ma Nivolumab Combination Therapy i Virus-fesoʻotaʻiga Tumors

O le mafuaʻaga o lenei suʻesuʻega e suʻesuʻe ai le saogalemu ma le aoga o le nivolumab, ma le nivolumab tuufaatasi togafitiga, e togafitia ai tagata mamaʻi o loʻo i ai siama e fesoʻotaʻi ma siama. O nisi siama ua lauiloa e faia se sao i tumo fausiaina ma le tuputupu ae. O lenei suʻesuʻega o le a suʻesuʻeina ai aʻafiaga o vailaʻau suʻesuʻe, i tagata mamaʻi o loʻo i ai ituaiga ituaiga o tuma nei - ituaiga kanesa - Merkel Cell Cancer - Kanesa kanesa-E le toe lesitalaina lenei ituaiga tuma - Vaʻaiga ma kanesa feula-E le toe lesitalaina lenei ituaiga tuma - Kanesa kanesa - E le toe lesitalaina lenei ituaiga tuma - Ao ma le Kanesa Kanesa - Le toe lesitalaina nei ituaiga tuma

Nofoaga: 10 nofoaga

Suesueina o Pembrolizumab (MK-3475) i Tagata Auai ma Advanced Tumors Tumau (MK-3475-158 / KEYNOTE-158)

I lenei suʻesuʻega, o sui auai e tele ituaiga o alualu i luma (le mafai ona tatalaina ma / pe faʻasolosolo) tuma malo na alualu i luma i le tulaga masani o le tausiga togafitiga o le a togafitia ma pembrolizumab.

Nofoaga: 8 nofoaga

Maualuga-Faʻataʻitaʻiga Brachytherapy ma Chemotherapy i le togafitia o tagata mamaʻi ma le toe maua i le lotoifale poʻo Residual Rectal poʻo le kanesa kanesa o loʻo faʻatautaia le faʻaaogaina

O lenei vaega ou te suʻesuʻeina suʻesuʻega o aʻafiaga ma sili ona lelei tui o le maualuga-fua-fua brachytherapy pe a tuʻufaʻatasia ma chemotherapy i le togafitia o tagata mamaʻi i le ponaivi poʻo le kanesa kanesa na toe foʻi mai pe na atili leaga ma e le mafai ona togafitia i se taotoga. Brachytherapy, lea e taʻua o le radiation radiation i totonu, e faʻaaoga ai mea e faʻaaoga i le leitio e tuʻu saʻo i totonu pe latalata i le tumo e fasioti ai sela tuma. Maualuga-inumaga-fua faatatau (HDR) brachytherapy faʻaaogaina le leitio mea e aumai ai le maualuga paʻu inumaga i se puʻupuʻu taimi o le taimi i le patu. E ono faʻaititia foʻi le paʻu ile laʻau maloloina e latalata ane ma ono faʻaititia ai aʻafiaga. O vailaʻau o loʻo faʻaaogaina i chemotherapy, pei o capecitabine ma fluorouracil, e eseese auala e taofi ai le tuputupu aʻe o sela tuma, a le o le fasiotia o sela, ala i le taofiina mai le vaeluaina, poʻo le taofia o latou mai le sosolo.

Nofoaga: 6 nofoaga

Pembrolizumab i le togafitia o tagata mamaʻi ma le Metastatic poʻo le tulaga o le kanesa o le kanesa o le tino e le mafai ona aveʻesea e taotoga.

Lenei vaega II suʻesuʻega suʻesuʻe pe faʻafefea ona galue le pembrolizumab i le togafitia o tagata mamaʻi ma le kanesa kanesa ua salalau atu i isi nofoaga o le tino pe na salalau mai lona amataga nofoaga o le tuputupu ae i lata ane aʻa poʻo lymph nodes ma le mafai ona aveʻesea e le taotoga. Immunotherapy ma monoclonal antibodies, pei o le pembrolizumab, ono fesoasoani i le tino o le tino puipuia osofaia le kanesa, ma ono faʻalavelave i le mafai o tumo sela e tupu ma salalau.

Nofoaga: 5 nofoaga

Taotoga i le togafitia o tagata mamaʻi ma le amataga o le kanesa o le kanesa poʻo le kanesa o le Perianal ma le lelei o le HIV

Lenei vaega II suʻesuʻega suʻesuʻe taotoga i le togafitia o tagata mamaʻi ma anal kanal po o le perianal kanesa e laʻititi ma e leʻi sosolo loloto i totonu o aano ma tagata puipuia siama puipuia (HIV) lelei. O taotoga i le lotoifale atonu o se togafitiga e sili atu le saogalemu ma le tele o aʻafiaga nai lo le tele o taotoga poʻo le radiation ma chemotherapy.

Nofoaga: 5 nofoaga

O se faʻataʻitaʻiga e suʻe ma suʻesuʻe ai se tulaga saogalemu o se vailaʻau fou (BI 754091) mo tagata mamaʻi ma tumors mautu.

O le autu autu o le fualaʻau-faʻateleina vaega o le faʻamasinoga o le fuafua le saogalemu ma le faʻapalepale, ma ia fuafuaina le Maximum Tolerated Dose ma / poʻo le Recommended Phase 2 Dose (RP2D) o le BI 754091 i luga o le faʻavae o tagata mamaʻi ma vailaʻau-faʻatapulaʻaina mea oona (DLTs) i tagata mamaʻi ua filifilia i ni gasegase faigata ua leva. O le saogalemu ma le faʻapalepale o le a iloiloina e ala i le vaʻavaʻaia o le tutupu o leaga mea tutupu (AEs), matuia AEs (SAE), ma falesuesue parameter mea le masani ai, faʻapea foi ma suiga i le taua faʻailoga. Manulauti sini o le fuafuaina o le PK talaʻaga o BI 754091 i le maeʻa tasi ma tele tui o BI 754091, ma le muamua faʻavasegaina o antitumour gaioiga. I le faʻalauteleina o fualaʻau vaega o le faʻamasinoga, o autu autu o le iloiloina atili o le saogalemu, aoga, PK faʻamatalaga,

Nofoaga: 3 nofoaga

Stereotactic Radiosurgery i le togafitia o tagata mamaʻi ma faʻamaʻi Oligometastatic

Lenei vaega II suʻesuʻega suʻesuʻe pe o le a le lelei o le stereotactic radiosurgery e galue ai i le togafitia o tagata mamaʻi ma le kanesa na salalau atu i le 5 pe itiiti ifo nofoaga i le tino ma aofia ai 3 pe itiiti ni totoga (oligometastatic faamaʻi). Stereotactic radiosurgery, lea e faʻaigoaina o le stereotactic body radiation therapy, o se faʻapitoa togafitiga faʻasolosolo e tuʻuina mai ai le tasi, maualuga fualaʻau o le faʻasasaʻo tuusao i le tumo ma ono fasiotia sili atu sela sela ma mafua ai le faʻaititia o laiga masani.

Nofoaga: 3 nofoaga

O se suʻesuʻega o le INCMGA00012 i le Squamous Carcinoma o le Kanala Vaʻaia Ina ua maeʻa le Platinum-Base Chemotherapy (POD1UM-202)

O le mafuaʻaga o lenei suʻesuʻega o le iloiloina o le aoga o le INCMGA00012 i tagata o loʻo auai ma le siʻosiʻomaga poʻo le metastatic squamous carcinoma o le anal canal (SCAC) ua alualu i luma ina ua maeʻa platinum-based chemotherapy.

Nofoaga: 4 nofoaga

Artesucky i le togafitia o tagata mamaʻi ma maualuga-vasega anal Intraepithelial Neoplasia

Lenei vaega ou suʻesuʻe suʻesuʻega o le itu aʻafiaga ma sili ona lelei tui o artesucky i le togafitia o tagata mamaʻi ma maualuga-vasega anal intraepithelial neoplasia. O le neoplasia o le vaega o loʻo i totonu o le iniseti o loʻo i totonu ole sela e ono avea pe kanesa ile lumanaʻi. Ole tele o suiga e maua ai ile kanesa e mafua mai ile tagata papillomavirus (HPV). Artesucky ono fasioti sela ua pisia i le HPV.

Nofoaga: 2 nofoaga

O se suʻesuʻega o le LY3434172, o le PD-1 ma le PD-L1 Bispecific Antibody, i le Advanced Cancer

O le autu mafuaʻaga o lenei suʻesuʻega o le iloiloina o le saogalemu ma le faʻapalepaleina o le suʻesuʻega fualaʻau LY3434172, o le PD-1 / PD-L1 bispecific antibody, i sui auai ma alualu i luma tuma.

Nofoaga: MD Anderson Cancer Center, Houston, Texas

SL-279252 (PD1-Fc-OX40L) i Mataupu Faʻafesoʻotaʻi Ma Tumua Maea Tumau poʻo Lymphomas

Lenei o le Vaega 1 muamua i le tagata, matala igoa, tele-ogatotonu, fualaʻau faʻateleina ma fualaʻau faʻalauteleina suʻesuʻega e iloilo ai le saogalemu, faʻapalepaleina, PK, anti-tuma gaioiga ma vailaʻau vailaʻau o SL-279252 i mataupu ma sili atu mautu tuma poʻo lymphomas .

Nofoaga: MD Anderson Cancer Center, Houston, Texas

LET-IMPT ma Standard Chemotherapy i le togafitia o tagata mamaʻi ma le tulaga fou o le I-III Anal Canal Squamous Cell Cancer

Lenei vaega II suʻesuʻega suesueina le itu aafiaga o LET-IMPT ma masani chemotherapy, ma le lelei latou galulue i le togafitia o tagata gasegase ma le fou na maua i le tulaga I-III anal canal squamous cell kanesa. LET-IMPT o se ituaiga togafitiga faʻasolosolo e faʻaaoga ai le malosi o le proton "beamlets" e "valivali" ai le vailaʻau o le radiation i le taulaʻiga ma ono fesoasoani e fasioti sela tuma ma faʻapipiʻi ai tagata. Faʻaavanoa LET-IMPT ma masani chemotherapy ono galue lelei i le togafitia tagata mamaʻi ma anal kanesa squamous sela kanesa.

Nofoaga: MD Anderson Cancer Center, Houston, Texas

VGX-3100 ma le Eletise i le togafitia o tagata mamaʻi ma le HIV-Positive High-grade anal lesion

Lenei vaega II tofotofoina suʻesuʻega pe faʻafefea ona lelei e le tagata papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids tui puipuia VGX-3100 (VGX-3100) ma le eletise galue i le togafitia o tagata mamaʻi ma le siama puipuia o le tino (HIV) O tui puipui e faia mai le DNA e ono fesoasoani i le tino e fausia ai se tali lelei mo le puipuia o sela tuma. O le eletise e fesoasoani i pu i sela o lou tino e ave ai fualaʻau e faʻamalosia ai le tali atu o lou tino O le tuʻuina atu o le VGX-3100 ma le faʻaaogaina o le eletise e mafai ona sili atu le lelei i le togafitia o tagata mamaʻi o loʻo maua i le tulaga maualuga.

Nofoaga: 2 nofoaga

DNA Plasmid-encoding Interleukin-12 / HPV DNA Plasmids Vailaʻau Toto INO-3112 ma Durvalumab i le togafitia o tagata mamaʻi ma le toe maua poʻo Metastatic Tagata Papillomavirus Fesoasoani faʻafitauli

Lenei vaega II suʻesuʻega suʻesuʻe pe faʻafefea ona lelei deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12 / human papillomavirus (HPV) DNA plasmids tui puipui INO-3112 ma le durvalumab galue i le togafitia o tagata mamaʻi ma papillomavirus fesoʻotaʻi kanesa ua toe foʻi mai pe salalau i isi nofoaga i le tino. O tui puipui e faia mai se siama e mafai ona fesoasoani i le tino e fausia ai se tali lelei mo le puipuia o sela tuma. Immunotherapy ma monoclonal antibodies, pei o le durvalumab, e ono fesoasoani i le tino o le tino i osofaʻiga o le kanesa, ma ono faʻalavelave ai ile mafai o sela tuma e tutupu ma sosolo. Le mauaina o le DNA plasmid-encoding interleukin-12 / HPV DNA plasmids therapeutic vaccine INO-3112 ma le durvalumab e mafai ona sili atu ona lelei i le togafitia o tagata mamaʻi ma papillomavirus e fesoʻotaʻi ma kanesa.

Nofoaga: MD Anderson Cancer Center, Houston, Texas

M7824 i mataupu ma faʻafitauli male HPV Associated Malignancies

Talaʻaga: I le Iunaite Setete, i tausaga taʻitasi e sili atu ma le 30,000 mataupu o tagata papillomavirus (HPV) fesoʻotaʻi ma kanesa. O nisi o nei kanesa e tele lava ina le mafai ona togafitia ma e le faʻaleleia e togafitiga masani. E manaʻo le au suʻesuʻe e vaʻai pe o se vailaʻau fou M7824, o loʻo faʻataʻatitia ma poloka ai se auala e puipuia ai le puipuiga o le tino mai le tauivi lelei ma le kanesa, e mafai ona faʻapipiʻi ai tagata o loʻo i ai kanesa o le HPV. Sini autu: Ia e vaai pe o le vailaʻau M7824 e mafua ai ona faʻavaivai tagata. Agavaʻa: Tagata matutua 18 tausaga ma sili atu o loʻo maua i le kanesa e fesoʻotaʻi ma faʻamaʻi HPV. Mamanu: O tagata auai o le a siakiina ma talaʻaga faʻasolopito ma faʻaletino suʻega. Latou te toe iloiloina a latou faʻailoga ma faʻafefea ona latou faia gaioiga masani. O le a latou maua tino suʻega. O le a latou tuʻuina atu le toto ma miaga faʻataʻitaʻiga. O le a latou maua se faʻataʻitaʻiga oo latou tuma sela faia pe a fai e le maua se tasi. Tagata auai o le a faia se electrocardiogram e iloilo ai o latou fatu. Ma o le a latou mauaina le suʻesuʻega fualaʻau ala i se manifinifi paipa i totonu o le uaua uaua. Tagata auai o le a mauaina le vailaʻau taʻitasi 2 vaiaso mo 26 taimi (1 tausaga). Lenei vasega 1. A maeʻa le vasega, o tagata o le a mataʻituina ae latou te le avea le suʻesuʻega vailaʻau. Afai o le a atili ai le leaga o latou tulaga, o le a latou amataina se isi vasega i le vailaʻau. Lenei faiga e mafai ona toe faia i le tele o taimi pe a manaʻomia. Togafitiga o le a taofia pe a fai o le tagata o loʻo i ai ni itu leaga poʻo le vailaʻau taofi le galue. I le taimi atoa o le suʻesuʻega, o le a toe faia ai e tagata o le vasega ni suʻega o suʻega. A maeʻa loa ona tagofia e sui le tagofia o fualaʻau, o le a faia se latou asiasiga faʻasolosolo ma toe faia nisi suʻega o suʻega. Latou te maua ni telefoni tulitatao tulitatao. ... Ma o le a latou mauaina le suʻesuʻega fualaʻau ala i se manifinifi paipa i totonu o le uaua uaua. Tagata auai o le a mauaina le vailaʻau taʻitasi 2 vaiaso mo 26 taimi (1 tausaga). Lenei vasega 1. A maeʻa le vasega, o tagata o le a mataʻituina ae latou te le avea le suʻesuʻega vailaʻau. Afai o le a atili ai le leaga o latou tulaga, o le a latou amataina se isi vasega i le vailaʻau. Lenei faiga e mafai ona toe faia i le tele o taimi pe a manaʻomia. Togafitiga o le a taofia pe a fai o le tagata o loʻo i ai ni itu leaga poʻo le vailaʻau taofi le galue. I le taimi atoa o le suʻesuʻega, o le a toe faia ai e tagata o le vasega ni suʻega o suʻega. A maeʻa loa ona tagofia e sui le tagofia o fualaʻau, o le a faia se latou asiasiga faʻasolosolo ma toe faia nisi suʻega o suʻega. Latou te maua ni telefoni tulitatao tulitatao. ... Ma o le a latou mauaina le suʻesuʻega fualaʻau ala i se manifinifi paipa i totonu o le uaua uaua. Tagata auai o le a mauaina le vailaʻau taʻitasi 2 vaiaso mo 26 taimi (1 tausaga). Lenei vasega 1. A maeʻa le vasega, o tagata o le a mataʻituina ae latou te le avea le suʻesuʻega vailaʻau. Afai o le a atili ai le leaga o latou tulaga, o le a latou amataina se isi vasega i le vailaʻau. Lenei faiga e mafai ona toe faia i le tele o taimi pe a manaʻomia. Togafitiga o le a taofia pe a fai o le tagata o loʻo i ai ni itu leaga poʻo le vailaʻau taofi le galue. I le taimi atoa o le suʻesuʻega, o le a toe faia ai e tagata o le vasega ni suʻega o suʻega. A maeʻa loa ona tagofia e sui le tagofia o fualaʻau, o le a faia se latou asiasiga faʻasolosolo ma toe faia nisi suʻega o suʻega. Latou te maua ni telefoni tulitatao tulitatao. ... tagata o le a mataituina ae o le a le avea le suʻega vailaʻau. Afai e faʻasolo ina leaga o latou tulaga, o le a latou amataina seisi vasega i le vailaʻau. Lenei faiga e mafai ona toe faia i le tele o taimi pe a manaʻomia. Togafitiga o le a taofia pe a fai o le tagata o loʻo i ai ni itu leaga poʻo le vailaʻau taofi le galue. I le taimi atoa o le suʻesuʻega, o le a toe faia ai e tagata o le vasega ni suʻega o suʻega. A maeʻa loa ona tagofia e sui le tagofia o fualaʻau, o le a faia se latou asiasiga faʻasolosolo ma toe faia nisi suʻega o suʻega. Latou te maua ni telefoni tulitatao tulitatao. ... tagata o le a mataituina ae o le a le avea le suʻega vailaʻau. Afai o le a atili ai le leaga o latou tulaga, o le a latou amataina se isi vasega i le vailaʻau. Lenei faiga e mafai ona toe faia i le tele o taimi pe a manaʻomia. Togafitiga o le a taofia pe a fai o le tagata o loʻo i ai ni itu leaga poʻo le vailaʻau taofi le galue. I le taimi atoa o le suʻesuʻega, o le a toe faia ai e tagata o le vasega ni suʻega o suʻega. A maeʻa loa ona tagofia e sui le tagofia o fualaʻau, o le a faia se latou asiasiga faʻasolosolo ma toe faia nisi suʻega o suʻega. Latou te maua ni telefoni tulitatao tulitatao. ... A maeʻa loa ona tagofia e sui le tagofia o fualaʻau, o le a faia se latou asiasiga faʻasolosolo ma toe faia nisi suʻega o suʻega. Latou te maua ni telefoni tulitatao tulitatao. ... A maeʻa loa ona tagofia e sui le tagofia o fualaʻau, o le a faia se latou asiasiga faʻasolosolo ma toe faia nisi suʻega o suʻega. Latou te maua ni telefoni tulitatao tulitatao. ...

Nofoaga: National Institutes of Health Clinical Center, Bethesda, Maryland

MnSOD Mimetic BMX-001 i le togafitia o tagata mamaʻi ma le kanesa kanesa o loʻo faia togafitiga faʻasolosolo ma togafitiga o le kanesa.

Lenei vaega I suʻesuʻega suesueina le sili fualaʻau o le MnSOD mimetic BMX-001 e faʻaititia ai aʻafiaga o tagata mamaʻi ma le kanesa kanesa o loʻo feagai ma togafitiga faʻafomaʻi ma chemotherapy. O vailaʻau ole chemoprotective, pei ole BMX-001, e ono puipuia ai sela masani mai le itu o le chemotherapy aʻo faʻamalosia le fasioti tagata.

Nofoaga: Iunivesite o Nebraska Medical Center, Omaha, Nebraska

Atezolizumab ma Bevacizumab i le togafitia o tagata gasegase ma le papala tino puta

Lenei vaega II suʻesuʻega suʻesuʻe pe o le a le lelei o le atezolizumab ma le bevacizumab e galue ai i le togafitia o tagata mamaʻi e seasea mauaa ni patu. Immunotherapy ma monoclonal antibodies, pei o atezolizumab ma bevacizumab, ono fesoasoani i le tino o le tino puipuia osofaia le kanesa, ma ono faʻalavelave i le mafai o tumo sela e tupu ma salalau.

Nofoaga: MD Anderson Cancer Center, Houston, Texas

Togafitiga togafitiga ma le Cyclophosphamide i le togafitia o tagata mamaʻi ma HLA-A * 02 Positive relapsed, Refractory, poʻo Metastatic HPV16-fesoʻotaʻi Oropharyngeal, faʻaʻautagata, poʻo kanesa kanesa

Lenei laʻasaga Ib / II suʻesuʻega suʻesuʻe aafiaga ma sili fualaʻau o HPV16-E711-19 nanomer tui DPX-E7 ma ia vaʻai pe faʻafefea ona aoga pe a tuʻuina faʻatasi ma le cyclophosphamide i le togafitia o tagata mamaʻi ma HLA-A * 02 lelei, tagata papillomavirus 16 ( HPV16)-fesoʻotaʻi oropharyngeal, faʻaʻautagata, poʻo kanesa kanesa ua toe foi mai, e le tali atu i togafitiga, pe ua salalau atu i isi vaega o le tino. O tui puipui e faia mai se siama e mafai ona fesoasoani i le tino e fausia ai se tali lelei mo le puipuia o sela tuma. O fualaʻau o loʻo faʻaaogaina i chemotherapy, pei o le cyclophosphamide, e galue i auala eseese e taofi ai le tuputupu aʻe o sela tuma, a le o le fasiotia o sela, ala i le taofiina latou mai le vaeluaina, poʻo le taofiina latou mai le sosolo. O le tuʻuina atu ole tui ole HPV16-E711-19 nanomer DPX-E7 faʻatasi ai ma le cyclophosphamide atonu e sili atu lona aoga ile togafitia o tagata mamaʻi ile HPV16-related oropharyngeal,

Nofoaga: Dana-Farber Cancer Institute, Boston, Massachusetts

Nivolumab ma Ipilimumab i le togafitia o tagata mamaʻi ma le papala o le tino

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for the following cohorts based on condition: 1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer [NPC], and squamous cell carcinoma of the head and neck [SCCHN]) B) Adenocarcinoma and variants of nasal cavity, sinuses, and nasopharynx (closed to accrual 07 / 27 / 2018) 2. Epithelial tumors of major salivary glands (closed to accrual 03 / 20 / 2018) 3. Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location (closed to accrual) 4. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Adenocarcinoma with variants of small intestine (closed to accrual 05 / 10 / 2018) 6. Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual 10 / 17 / 2018) 7. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03 / 20 / 2018) 8. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Pancreatic adenocarcinoma is not eligible 9. Intrahepatic cholangiocarcinoma (closed to accrual 03 / 20 / 2018) 10. Extrahepatic cholangiocarcinoma and bile duct tumors (closed to accrual 03 / 20 / 2018) 11. Sarcomatoid carcinoma of lung 12. Bronchoalveolar carcinoma lung. This condition is now also referred to as adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma 13. Non-epithelial tumors of the ovary: A) Germ cell tumor of ovary B) Mullerian mixed tumor and adenosarcoma (closed to accrual 03 / 30 / 2018) 14. Trophoblastic tumor: A) Choriocarcinoma (closed to accrual 04 / 15 / 2019) 15. Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder (closed to accrual 04 / 15 / 2019) 16. Cell tumor of the testes and extragonadal germ tumors: A) Seminoma and testicular sex cord cancer B) Non-seminomatous tumor C) Teratoma with malignant transformation (closed to accrual 3 / 15 / 2019) 17. Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis 18. Squamous cell carcinoma variants of the genitourinary (GU) system 19. Spindle cell carcinoma of kidney, pelvis, ureter 20. Adenocarcinoma with variants of GU system (excluding prostate cancer) (closed to accrual 07 / 27 / 2018) 21. Odontogenic malignant tumors 22. Pancreatic neuroendocrine tumor (PNET) (formerly named: Endocrine carcinoma of pancreas and digestive tract.) 23. Neuroendocrine carcinoma including carcinoid of the lung (closed to accrual 12 / 19 / 2017) 24. Pheochromocytoma, malignant 25. Paraganglioma (closed to accrual 11 / 29 / 2018) 26. Carcinomas of pituitary gland, thyroid gland parathyroid gland and adrenal cortex 27. Desmoid tumors 28. Peripheral nerve sheath tumors and NF1-related tumors (closed to accrual 09 / 19 / 2018) 29. Malignant giant cell tumors 30. Chordoma (closed to accrual 11 / 29 / 2018) 31. Adrenal cortical tumors (closed to accrual 06 / 27 / 2018) 32. Tumor of unknown primary (Cancer of Unknown Primary; CuP) (closed to accrual 12 / 22 / 2017) 33. Not Otherwise Categorized (NOC) Rare Tumors [To obtain permission to enroll in the NOC cohort, contact: S1609SC@swog.org] (closed to accrual 03 / 15 / 2019) 34. Adenoid cystic carcinoma (closed to accrual 02 / 06 / 2018) 35. Vulvar cancer 36. MetaPLASTIC carcinoma (of the breast) 37. Gastrointestinal stromal tumor (GIST) (closed to accrual 09 / 26 / 2018) 38. Perivascular epithelioid cell tumor (PEComa) 39. Apocrine tumors / extramammary Paget’s disease 40. Peritoneal mesothelioma 41. Basal cell carcinoma 42. Clear cell cervical cancer 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (malignant mixed Mullerian tumors) (closed to accrual) 45. Clear cell cervical endometrial cancer 46. Clear cell ovarian cancer 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Small cell carcinoma of the ovary, hypercalcemic type 50. PD-L1 amplified tumors 51. Angiosarcoma 52. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine tumor [PNET] should be enrolled in Cohort 22; prostatic neuroendocrine carcinomas should be enrolled into Cohort 53). Small cell lung cancer is not eligible 53. Treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC)

Nofoaga: 878 nofoaga